MX2015012716A - Compositions for use in treating eye disorders using dipyridamole. - Google Patents

Compositions for use in treating eye disorders using dipyridamole.

Info

Publication number
MX2015012716A
MX2015012716A MX2015012716A MX2015012716A MX2015012716A MX 2015012716 A MX2015012716 A MX 2015012716A MX 2015012716 A MX2015012716 A MX 2015012716A MX 2015012716 A MX2015012716 A MX 2015012716A MX 2015012716 A MX2015012716 A MX 2015012716A
Authority
MX
Mexico
Prior art keywords
dipyridamole
compositions
eye disorders
treating eye
topically
Prior art date
Application number
MX2015012716A
Other languages
Spanish (es)
Inventor
Moshe Rogosnitzky
Original Assignee
Remedeye Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedeye Inc filed Critical Remedeye Inc
Publication of MX2015012716A publication Critical patent/MX2015012716A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention discloses compositions for use in treating eye disorders, the compositions including an effective amount of a topically-administered dipyridamole. Preferably, the topically-administered dipyridamole is formulated as a solution. Preferably, the topically-administered dipyridamole is at least one agent selected from the group consisting of: dipyridamole, and a pharmaceutically-acceptable salt thereof. Preferably, the effective amount corresponds to a concentration of at least about 10-5 molarity. Preferably, the effective amount is based on a treatment administration of at least once every other day.
MX2015012716A 2013-03-12 2014-03-11 Compositions for use in treating eye disorders using dipyridamole. MX2015012716A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL225179A IL225179A (en) 2013-03-12 2013-03-12 Compositions for use in treating eye disorders using dipyridamole
PCT/IB2014/059645 WO2014141079A1 (en) 2013-03-12 2014-03-11 Compositions for use in treating eye disorders using dipyridamole

Publications (1)

Publication Number Publication Date
MX2015012716A true MX2015012716A (en) 2016-07-06

Family

ID=48916407

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012716A MX2015012716A (en) 2013-03-12 2014-03-11 Compositions for use in treating eye disorders using dipyridamole.

Country Status (14)

Country Link
EP (1) EP2968328A4 (en)
JP (1) JP6820658B2 (en)
KR (2) KR20150126021A (en)
CN (1) CN105188702B (en)
AU (1) AU2014229371B2 (en)
BR (1) BR112015022084A2 (en)
CA (1) CA2905594A1 (en)
CL (1) CL2015002627A1 (en)
EA (1) EA035966B1 (en)
IL (1) IL225179A (en)
MX (1) MX2015012716A (en)
MY (1) MY182591A (en)
SG (2) SG10201706937UA (en)
WO (1) WO2014141079A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3250201A4 (en) * 2015-01-28 2018-08-01 Realinn Life Science Limited Compounds for enhancing ppar expression and nuclear translocation and therapeutic use thereof
US20180092776A1 (en) 2016-09-30 2018-04-05 Sara Heikali Method and device for treating and managing diseased ocular tissue
WO2021001806A1 (en) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations with reduced impurities
WO2021001805A1 (en) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations and their methods of preparation
WO2024125322A1 (en) * 2022-12-16 2024-06-20 智泽童康(广州)生物科技有限公司 Dipyridamole for preventing and treating allergic and/or inflammatory diseases and preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258084A (en) * 1994-03-17 1995-10-09 Rohto Pharmaceut Co Ltd Intracular pressure-reducing agent containing dipyridamole as essential component
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
ZA200804550B (en) * 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
WO2010056710A1 (en) * 2008-11-11 2010-05-20 Biovista, Inc. Compositions and methods for treating eye diseases
EP2363126A1 (en) * 2010-03-04 2011-09-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition comprising as active ingredient L-carnitine in combination with hydroxykynurenine-O-beta-DL-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation

Also Published As

Publication number Publication date
CL2015002627A1 (en) 2016-03-11
JP6820658B2 (en) 2021-01-27
CN105188702B (en) 2019-03-26
IL225179A (en) 2017-01-31
SG11201507092QA (en) 2015-10-29
BR112015022084A2 (en) 2017-07-18
EP2968328A4 (en) 2016-11-23
MY182591A (en) 2021-01-26
SG10201706937UA (en) 2017-09-28
EP2968328A1 (en) 2016-01-20
EA035966B1 (en) 2020-09-07
AU2014229371B2 (en) 2018-05-10
KR20150126021A (en) 2015-11-10
CA2905594A1 (en) 2014-09-18
CN105188702A (en) 2015-12-23
AU2014229371A1 (en) 2015-10-29
WO2014141079A1 (en) 2014-09-18
KR20210010638A (en) 2021-01-27
IL225179A0 (en) 2013-06-27
JP2016514123A (en) 2016-05-19
EA201591653A1 (en) 2017-05-31

Similar Documents

Publication Publication Date Title
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MX364486B (en) Pyridazinone-amides derivatives.
EA201890641A2 (en) STIMULATORS sGC
IN2015DN01156A (en)
MX365294B (en) Dna-pk inhibitors.
MX368833B (en) Quinoline and quinazoline amides as modulators of sodium channels.
MX365939B (en) Nuclear transport modulators and uses thereof.
MX2015009444A (en) Novel traps in the treatment of macular degeneration.
MX2018003893A (en) Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough.
EA201892726A1 (en) DEUTERED PALBOCYCLIB
MX2016005668A (en) Crystalline forms of therapeutic compounds and uses thereof.
UA117032C2 (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma
EA201692481A1 (en) COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
UA115357C2 (en) Pyridin-4-yl derivatives
MY182591A (en) Compositions for use in treating eye disorders using dipyridamole
MX2016016404A (en) Methods for treating pruritus.
EA201591434A1 (en) METHOD OF PROVIDING THE EYE NEUROPROTECTION
EP2910247A4 (en) Compositions for preventing or treating allergic skin disorders, containing gpcr19 agents as active ingredients
IN2013MU03773A (en)
EA201491878A1 (en) SUBSTITUTED XANTHINE DERIVATIVES
MX366805B (en) Use of zinc coceth sulfate as an antibacterial agent against propionibacterium acnes.
MX2016014261A (en) Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis.